In consequence, a patient known to be a carrier could receive PARP inhibitors early in treatment (Banerjee et al, 2010), making clinical genetic testing of RAD51D mutations in BRCA1/2-negative patients with one or more familial ovarian cancers in the pedigree potentially highly beneficial. Here, BRCA1 is linked to ovarian carcinoma.